Welcome to our dedicated page for IRADIMED SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRADIMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRADIMED's regulatory disclosures and financial reporting.
Iradimed Corporation director James B. Hawkins reported the vesting and conversion of restricted stock units into common stock. On December 7, 2025, 1,197 restricted stock units converted into 1,197 shares of Iradimed common stock at an exercise price of $0, reflecting a standard equity grant vesting.
These units were granted on December 7, 2023 under Iradimed's 2023 Equity Incentive Plan and vest in two equal annual installments beginning December 7, 2024. Following this transaction, Hawkins beneficially owns 31,742 shares of Iradimed common stock directly.
IRADIMED Corporation (IRMD) CEO, president, chairman and director Roger E. Susi reported insider sales of common stock on 11/24/2025. Through the Phillip Susi 2008 Dynasty Trust, he sold a total of 5,000 shares in three transactions: 556 shares at a weighted average price of $89.67, 3,558 shares at $90.31, and 886 shares at $91.01, all coded as open market sales.
These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After the reported transactions, the Phillip Susi 2008 Dynasty Trust beneficially owns 2,307,500 shares, with additional indirect holdings reported through other trusts.
IRADIMED CORP director reports open-market stock sales. A reporting person serving as a director of IRADIMED CORP (ticker IRMD) disclosed several open-market sales of common stock on 11/20/2025. The transactions, all coded as sales, totaled 3,000 shares at prices ranging from $88.00 to $88.50 per share. After these trades, the director beneficially owned 30,545 shares of IRADIMED common stock in direct ownership. This filing is a routine Form 4 disclosure of insider trading activity and does not describe any company-level operational or financial changes.
IRADIMED Corporation (IRMD) CEO Roger E. Susi, who is also a director, chairman and 10% owner, reported indirect sales of company common stock on 11/18/2025. A trust for his benefit, the Phillip Susi 2008 Dynasty Trust, sold 3,184 shares at a weighted average price of $85.29 and 1,816 shares at a weighted average price of $86.12, in transactions coded as open-market sales. These trades were made under a Rule 10b5-1 trading plan adopted on June 16, 2025. After the reported transactions, indirect beneficial holdings remain in multiple trusts, including over two million shares held through the Phillip Susi 2008 Dynasty Trust.
IRADIMED CORP (IRMD) reported an insider transaction on Form 4 by CEO, President, Chairman and Director Roger E. Susi, who is also a 10% owner. On 11/10/2025, he reported two open-market sales of common stock coded “S”.
He sold 2,252 shares at a weighted average price of $84.59 (individual trades ranged from $84.27 to $85.01) and 2,748 shares at a weighted average price of $85.77 (range $85.29 to $86.09). The sales were effected under a Rule 10b5-1 trading plan adopted on June 16, 2025.
Following these transactions, reported indirect holdings include 2,317,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, as disclosed.
IRADIMED CORP (IRMD) filed a Form 4 reporting an insider sale. The company’s Chief Financial Officer sold 10,651 shares of common stock on 11/10/2025, coded “S” for an open-market sale, at a weighted average price of $84.5143. Following the transaction, the reporting person directly holds 2,500 shares. The sale was executed in multiple trades within a price range of $84.25 to $85.18, with the weighted average provided; full trade details are available upon request.
IRADIMED Corp (IRMD) CEO, President, Chairman and Director Roger E. Susi reported open-market sales of common stock on November 3, 2025.
The filing lists six tranches by an indirect holder, the Phillip Susi 2008 Dynasty Trust, including 1,618 shares at a weighted average price of $83.85, 1,335 shares at $83.22, 900 shares at $81.71, 601 shares at $81.28, 446 shares at $79.82, and 100 shares at $84.60. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
Following the reported transactions, the filing shows 2,322,500 shares held indirectly by the Phillip Susi 2008 Dynasty Trust, 162,950 shares held indirectly by the Roger E. Susi Revocable Trust, and 2,062,500 shares held indirectly by the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of certain securities except to the extent of pecuniary interest.
IRADIMED CORPORATION reported solid growth for the quarter ended September 30, 2025, with revenue of $21.2 million, up 16% year over year. Net income was $5.6 million and diluted EPS was $0.43. Gross margin improved to 78% as device sales led results, including MRI-compatible IV infusion pumps at $8.3 million and patient monitoring systems at $6.9 million. U.S. revenue grew 19% to $18.1 million, while international revenue was $3.1 million.
Operating income rose to $6.8 million as operating expenses increased with higher sales activity and payroll. Cash and cash equivalents were $56.5 million, and contract liabilities rose to $6.7 million, reflecting growth in maintenance agreements and advance customer payments. The company completed its new Orlando facility and announced FDA 510(k) clearance for the next‑generation MRidium 3870, with an initial rollout planned in Q4 2025. The Board declared a regular cash dividend of $0.17 per share, payable November 25, 2025 to holders of record on November 14, 2025. Shares outstanding were 12,721,156 as of October 31, 2025.
IRADIMED CORPORATION filed a Form 8-K to report that it issued a press release on November 3, 2025 announcing its financial results for the quarter ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and is designated as “furnished,” not “filed,” meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings.
IRADIMED (IRMD) insider activity: CEO/President/Chairman and 10% owner Roger E. Susi filed a Form 4 reporting open‑market sales on 10/27/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.
The filing shows three sales by an indirect holder: 4,242 shares at a weighted average price of $77.56, 700 shares at $78.33, and 58 shares at $79.12. Following these transactions, 2,327,500 shares were beneficially owned indirectly by the Phillip Susi 2008 Dynasty Trust. Additional indirect holdings listed include 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with a stated disclaimer of beneficial ownership except to the extent of pecuniary interest.